Quarterly report pursuant to Section 13 or 15(d)

Royalty Purchase Agreements - Agenus (Details)

v3.20.2
Royalty Purchase Agreements - Agenus (Details)
$ in Thousands
 6 Months Ended 12 Months Ended
Sep. 20, 2018
USD ($)
product
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Agreements        
Payments to acquire milestones and royalties     $ 6,300  
Proceeds from issuance of long-term debt     $ 3,000  
Changes in estimated fair value of contingent consideration   $ 0    
Long-term royalty receivables   34,375   $ 34,375 [1]
Impairment of long-term royalty receivable   0   $ 0
Royalty Purchase Agreement | Agenus        
Agreements        
Payments to acquire milestones and royalties $ 15,000      
Long-term royalty receivables 15,000      
Impairment of long-term royalty receivable   $ 0    
Royalty Purchase Agreement | Agenus | Silicon Valley Bank Loans        
Agreements        
Proceeds from issuance of long-term debt $ 7,500      
Royalty Purchase Agreement | Agenus | Incyte Immuno-Oncology Assets        
Agreements        
Royalties on net sales of products (as a percent) 33.00%      
Number of licensed products related to milestone and royalties | product 6      
Purchased percentage of milestones 10.00%      
Royalty Purchase Agreement | Agenus | Merck Immuno-Oncology Product        
Agreements        
Royalties on net sales of products (as a percent) 33.00%      
Purchased percentage of milestones 10.00%      
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500      
[1] The consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.